Please use this identifier to cite or link to this item:
|Title:||Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin|
Thailand Ministry of Public Health
The HIV Netherlands Australia Thailand Research Collaboration
Bamrasnaradura Infectious Disease Institute
|Keywords:||Immunology and Microbiology|
|Citation:||Clinical Infectious Diseases. Vol.43, No.2 (2006), 253-255|
|Abstract:||Seventy human immunodeficiency virus (HIV)-infected patients receiving rifampicin and 70 HIV-infected patients not receiving rifampicin were enrolled to receive 400 mg of nevirapine-based highly active antiretroviral therapy per day. Mean plasma nevirapine levels at 8 and 12 weeks were lower in patients receiving rifampicin (P = .048). However, virological and immunological outcomes at 24 weeks were not different between the 2 groups (P > .05). © 2006 by the Infectious Diseases Society of America. All rights reserved.|
|Appears in Collections:||Scopus 2006-2010|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.